**Supplementary Table.**

The 63 ALS- or other MNDs-related genes examined in this study.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| *ALS2* | *SETX* | *TUBA4A* | *PLEKHG5* | *DNAJB2* |
| *ANG* | *SIGMAR1* | *CHCHD10* | *SMN1* | *DYNC1H1* |
| *ATXN2* | *SOD1* | *TBK1* | *TRPV4* | *BICD2* |
| *C9ORF72* | *SPG11* | *EWSR1* | *VRK1* | *FBXO38* |
| *CHMP2B* | *TAF15* | *SQSTM1* | *HSPB1* | *ASAH1* |
| *DAO* | *TARDBP* | *SS18L1* | *HSPB3* | *EXOSC8* |
| *DCTN1* | *UBQLN2* | *GLE1* | *HSPB8* | *EXOSC3* |
| *FIG4* | *VAPB* | *GRN* | *ATL1* | *SLC52A3* |
| *FUS* | *VCP* | *ZNF512B* | *SPAST* | *SLC52A2* |
| *NEFH* | *ERBB4* | *ATP7A* | *AARS* | *HEXB* |
| *OPTN* | *HNRNPA1* | *BSCL2* | *REEP1* | *MAPT* |
| *PFN1* | *HNRNPA2B1* | *GARS* | *SLC5A7* |  |
| *PRPH* | *MATR3* | *IGHMBP2* | *UBA1* |  |

ALS, amyotrophic lateral sclerosis; MNDs, motor neuron diseases

The targeted regions were designed to include coding exons with intronic 25 bp flanking sites and 3′ and 5′ untranslated regions (UTRs) by using the SureDesign system (Agilent Technologies, Santa Clara, CA, USA). The regional source of coding exons was extracted from the RefSeq, CCDS, Ensemble, Gencode, SNP or CytoBand databases. The target coverage was expected to be 98.85%.